Karin Schmitt

Mursla Ltd. is a liquid biopsy company based in the UK. The British company uses a novel tech platform called exopheno™ to trace diseases in biofluids via exosomes. Mursla is developing its platform to detect dozens of cancer types with a single blood test, starting with liver cancer surveillance. The company was founded by Pierre Arsène, who has been the CEO since incorporation.

Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom.

Open Biosystems, Inc. develops biotechnology solutions. Its products include gene editing, RNA interference, custom RNA synthesis, gene expression (CDNAS and ORFS), transfection and viral packaging. The company was founded by Troy Moore in 2001 and is headquartered in Montgomery, AL.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.